Home The Word Brain	My Amedeo FAQ Privacy About
	As of October 2023, Amedeo had 12,263 active subscribers

Inflammatory Bowel Diseases

Free Subscription Articles published in Lancet Retrieve available abstracts of 16 articles: HTML format

Single Articles

August 2023
1. LE BERRE C, Honap S, Peyrin-Biroulet L
   Ulcerative colitis.
   Lancet. 2023;402:571-584.
   PubMed     Abstract available
   
   
   March 2023
2. SANDBORN WJ, Vermeire S, Peyrin-Biroulet L, Dubinsky MC, et al
   Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies.
   Lancet. 2023 Mar 2:S0140-6736(23)00061-2. doi: 10.1016/S0140-6736(23)00061.
   PubMed     Abstract available
   
   
   
3. ATREYA R, Neurath MF
   The sphingosine-1-phosphate receptor agonist etrasimod in ulcerative colitis.
   Lancet. 2023 Mar 2:S0140-6736(23)00228-3. doi: 10.1016/S0140-6736(23)00228.
   PubMed    
   
   
   June 2022
4. SANDS BE, Irving PM, Hoops T, Izanec JL, et al
   Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial.
   Lancet. 2022;399:2200-2211.
   PubMed     Abstract available
   
   
   
5. CHAPMAN TP, Satsangi J
   Head-to-head biologic therapy in Crohn's disease.
   Lancet. 2022;399:2169-2171.
   PubMed    
   
   
   
6. BANARES J, Aceituno L, Jimenez A, Maynard A, et al
   Sweet's syndrome and Crohn's disease diagnosed simultaneously.
   Lancet. 2022;399:2155.
   PubMed    
   
   
   May 2022
7. FERRANTE M, Panaccione R, Baert F, Bossuyt P, et al
   Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial.
   Lancet. 2022;399:2031-2046.
   PubMed     Abstract available
   
   
   
8. D'HAENS G, Panaccione R, Baert F, Bossuyt P, et al
   Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials.
   Lancet. 2022;399:2015-2030.
   PubMed     Abstract available
   
   
   
9. HIBI T
   Risankizumab for Crohn's disease.
   Lancet. 2022;399:1992-1993.
   PubMed    
   
   
   
10. DANESE S, Vermeire S, Zhou W, Pangan AL, et al
    Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials.
    Lancet. 2022 May 26. pii: S0140-6736(22)00581.
    PubMed     Abstract available
    
    
    
11. ANANTHAKRISHNAN AN
    Upadacitinib for ulcerative colitis.
    Lancet. 2022 May 26. pii: S0140-6736(22)00778.
    PubMed    
    
    
    August 2021
12. MCLORNAN DP, Pope JE, Gotlib J, Harrison CN, et al
    Current and future status of JAK inhibitors.
    Lancet. 2021;398:803-816.
    PubMed     Abstract available
    
    
    July 2021
13. RAMSPOTT JP, Neureiter D, Emmanuel K, Jager T, et al
    Granulomatosis with polyangiitis presents with skip lesions of the bowel.
    Lancet. 2021;398:e8.
    PubMed    
    
    
    
14. SMERAT T, Khdour M, Abdoh Q, Hallak H, et al
    Assessment of health-related quality of life in patients with inflammatory bowel disease in occupied Palestinian territory: a correlation cross-sectional study.
    Lancet. 2021;398 Suppl 1:S48.
    PubMed     Abstract available
    
    
    June 2021
15. HOLMER AK, Singh S
    Expanding targeted immune modulators in ulcerative colitis.
    Lancet. 2021 Jun 3. pii: S0140-6736(21)00891.
    PubMed    
    
    
    
16. FEAGAN BG, Danese S, Loftus EV Jr, Vermeire S, et al
    Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial.
    Lancet. 2021 Jun 3. pii: S0140-6736(21)00666.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Inflammatory Bowel Diseases is free of charge.